Buy CJC-1295 With DAC For Lab Research

CJC-1295 With DAC | Buy CJC-1295 DAC UK | Long-Acting GHRH Analogue | Research Use Only

CJC-1295 With DAC (DAC:GRF — Drug Affinity Complex: Growth Hormone-Releasing Factor) is a synthetic, tetra-substituted 30-amino acid analogue of human GHRH (1-29) incorporating a unique Drug Affinity Complex that enables covalent, in vivo bioconjugation to endogenous serum albumin — extending its plasma half-life to approximately 6–8 days and making it the longest-acting GHRH-class research compound characterised to date. It is studied in laboratory research for its role in sustained GH and IGF-1 axis elevation, somatotroph biology, pituitary reserve research, GH/IGF-1 serum proteomics, GHRH-knockout growth normalisation models, and sustained versus pulsatile GH secretion comparative pharmacology — available to buy in the UK from Peptides Lab UK in high-purity lyophilised form, >99% HPLC-verified purity, with batch-specific COA and fast UK dispatch for laboratory and in vitro research use only.

Distributed by Peptides Lab UK in a high-purity lyophilised format, for laboratory research use only. This compound is handled in controlled settings for in vitro and pre-clinical studies, with no applications in human or veterinary medicine. Each batch undergoes rigorous quality analysis to ensure >99% purity (HPLC verified).

What Is CJC-1295 With DAC?

CJC-1295 DAC, also known as DAC:GRF (Drug Affinity Complex: Growth Hormone-Releasing Factor), is a synthetic analogue of growth hormone-releasing hormone (GHRH) and a growth hormone secretagogue (GHS) developed by ConjuChem Biotechnologies. It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regard to half-life, and has been shown to markedly increase plasma growth hormone and insulin-like growth factor-1 levels in animals and humans.

CJC-1295 with DAC was identified through a systematic screening programme in which three maleimido derivatives of hGRF(1-29) were synthesised and bioconjugated to human serum albumin ex vivo. All three conjugates showed enhanced in vitro stability against dipeptidylpeptidase-IV and were bioactive in a GH secretion assay in cultured rat anterior pituitary cells. CJC-1295 — a tetrasubstituted form of hGRF(1-29) with an added Nε-3-maleimidopropionamide derivative of lysine at the C-terminus — was selected as the lead compound, with Western blot analysis confirming the presence of a CJC-1295 immunoreactive species on the serum albumin band appearing after 15 minutes and remaining in circulation beyond 24 hours post-injection.

CJC-1295 DAC has an extended half-life of 8–10 days in humans, due to its ability to bind to endogenous serum albumin through a free thiol group forming a covalent disulfide bond — a mechanism that fundamentally distinguishes it from all other GHRH analogues in the research class.

What sets CJC-1295 DAC apart from its no-DAC counterpart, Sermorelin, and Tesamorelin is not merely pharmacokinetic — it is the unique DAC bioconjugation mechanism itself, which transforms a short-acting GHRH peptide into a near-continuous upstream GH axis driver. This creates a profoundly different experimental context: rather than studying discrete GH pulse events, researchers using CJC-1295 DAC study the biological consequences of sustained, days-long GHRH-receptor engagement — including effects on somatotroph proliferation, GH mRNA transcription, serum proteome remodelling, and the preservation of GH pulsatility under continuous upstream stimulation.

As a research compound, CJC-1295 DAC UK is the most extensively published long-acting GHRH analogue in the scientific literature, with two randomised, placebo-controlled, double-blind clinical trials, pre-clinical GHRH-knockout mouse data, and serum proteomics research all contributing to its well-characterised pharmacological profile.

How Does CJC-1295 With DAC Work?

The DAC Albumin-Binding Mechanism

The extended half-life of CJC-1295 DAC is achieved through in vivo bioconjugation: the maleimidopropionamide lysine derivative at the C-terminus reacts with the free thiol group on Cys34 of endogenous serum albumin following subcutaneous injection, forming a stable covalent bond. Because albumin has a circulating half-life of approximately 19 days and is present at ~40 g/L in plasma, the conjugated peptide is effectively protected from renal clearance and proteolytic degradation — resulting in the compound remaining pharmacologically active for 6–8 days from a single injection.

GHRH Receptor Activation and cAMP/PKA Signalling

CJC-1295 DAC acts primarily by binding to GHRH receptors on somatotroph cells in the anterior pituitary, activating intracellular cascades including cyclic AMP generation and protein kinase A activation — enhancing transcription of GH and secretion of hormone granules. This is the same canonical Gs/adenylate cyclase pathway engaged by all GHRH-class compounds, but the DAC modification sustains this receptor engagement over days rather than minutes.

Sustained GH Trough Elevation with Preserved Pulsatility

A key finding distinguishing CJC-1295 DAC from direct GH administration is that GH pulsatility is preserved despite continuous GHRH-receptor stimulation. A study assessing GH pulsatility by 20-minute blood sampling during 12-hour overnight periods found that GH secretion was increased after CJC-1295 administration with preserved pulsatility — with the greatest enhancement occurring in trough GH levels, which increased 7.8-fold — and concluded that continuous GHRH stimulation markedly enhances trough GH while maintaining the pulsatile architecture essential for physiological GH axis function.

Somatotroph Proliferation and GH mRNA Upregulation

Beyond acute GH secretion, CJC-1295 DAC has been demonstrated to stimulate somatotroph cell proliferation and pituitary reserve. In GHRH-knockout mice, CJC-1295 caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images — establishing that sustained GHRH-R engagement via the DAC mechanism acts on multiple levels of GH axis biology, not merely triggering existing secretory capacity but actively expanding it.

Serum Proteome Remodelling

Two-dimensional gel electrophoresis of serum samples from healthy adult males before and one week after CJC-1295 injection identified five protein spots displaying significant changes — including decreased apolipoprotein A1 and transthyretin isoforms, and increased beta-hemoglobin, C-terminal albumin fragments, and an immunoglobulin/albumin mixed fragment — with a linear relationship found between the albumin/immunoglobulin fragment and IGF-1 levels, suggesting these represent potential biomarkers of GH and IGF-1 action useful in detecting sustained GH axis activation.

What Does CJC-1295 With DAC Do in Research?

In laboratory and pre-clinical settings, CJC-1295 DAC has been studied across a range of GH axis and metabolic biology models. Research has examined its role in:

• Sustained GHRH receptor engagement and cAMP/PKA somatotroph signalling under continuous stimulation
• GH trough and mean concentration elevation studies — with preserved pulsatile architecture
• Somatotroph cell proliferation, pituitary reserve expansion, and GH mRNA transcriptional upregulation
• IGF-1 axis sustained elevation and downstream anabolic pathway investigations
• GH/IGF-1-driven serum proteome remodelling and biomarker discovery research
• GHRH-knockout (GHRHKO) mouse growth normalisation and interval-dependent dosing models
• Comparative sustained vs pulsatile GH secretion biology — CJC-1295 DAC vs no-DAC and Sermorelin
• Metabolic pathway research — lipid oxidation, glucose homeostasis, and body composition modelling
• Lean mass preservation and subcutaneous fat mass normalisation in GH-deficient models
• GH axis feedback regulation — somatostatin interplay under days-long GHRH-R occupancy

CJC-1295 DAC and GH/IGF-1 Elevation Research

In two randomised, placebo-controlled, double-blind, ascending-dose trials in healthy subjects aged 21–61 years, single subcutaneous injections of CJC-1295 produced dose-dependent increases in mean plasma GH concentrations of 2 to 10-fold for 6 days or more, and in mean plasma IGF-1 concentrations of 1.5 to 3-fold for 9–11 days. With multiple doses, mean IGF-1 levels remained elevated for up to 28 days, with evidence of a cumulative effect. No serious adverse reactions were reported.

CJC-1295 DAC and GHRH-Knockout Research

In GHRH-knockout mice — a model of isolated GH deficiency where even twice-daily injections of conventional GHRH analogues are unable to normalise growth — CJC-1295 DAC at daily doses of 2 µg completely normalised body weight and length over 5 weeks of treatment, with femur and tibia length maintained in the daily and 48-hourly groups. Relative lean mass and subcutaneous fat mass were normal in all treated groups.

CJC-1295 DAC and Somatotroph Biology

In GHRH-knockout mice, CJC-1295 caused a 13-, 9-, and 7-fold increase in total pituitary RNA in the 24-, 48-, and 72-hourly treatment groups respectively compared to placebo — reflected in 11-, 8-, and 6-fold increases in GH mRNA. When corrected for daily dose, these figures equated to comparable 13–16-fold GH mRNA increases per day of treatment across all groups, with immunohistochemistry confirming proliferation of GH-positive somatotroph cells — findings that establish CJC-1295 DAC’s capacity to expand pituitary somatotroph reserve beyond simple secretagogue activity.

CJC-1295 DAC and GH Pulsatility Research

Research specifically designed to assess whether prolonged GHRH stimulation abolishes GH pulsatility — a key concern for sustained GH secretagogue research models — found that GH secretion was increased after CJC-1295 administration with fully preserved pulsatility. Trough and mean GH secretion were both elevated, with the marked enhancement of trough GH levels identified as the primary mechanism driving increased IGF-1 production. This preservation of pulsatile architecture under days-long GHRH-R occupancy is a defining pharmacological characteristic of CJC-1295 DAC that distinguishes it from direct GH administration.

CJC-1295 DAC and Serum Proteomics Research

CJC-1295 DAC presents as a uniquely powerful tool for GH/IGF-1 axis proteomics research, with one week of sustained axis elevation producing statistically significant changes in five identified serum protein spots — including apolipoprotein A1, transthyretin, beta-hemoglobin, and albumin fragments — establishing a platform for identifying novel biomarkers of sustained GH axis activity that extends well beyond standard IGF-1 and IGFBP-3 measurement.

What Do Studies Say About CJC-1295 With DAC?

CJC-1295 DAC carries the most extensively published clinical research profile of any GHRH analogue currently available as a research compound, with two randomised controlled trials in healthy adults, pre-clinical knockout mouse data, and a serum proteomics study providing a well-rounded evidence base.

The Landmark Phase 2 Clinical Trials

Two randomised, placebo-controlled, double-blind trials — the first 28 days in duration and the second 49 days — established the foundational pharmacological profile of CJC-1295 DAC in healthy adults. The estimated half-life was confirmed at 5.8–8.1 days. Subcutaneous administration resulted in sustained, dose-dependent increases in GH and IGF-1 levels, and was safe and relatively well tolerated, particularly at doses of 30 or 60 µg/kg — with the authors concluding that the data support the potential utility of CJC-1295 as a therapeutic research tool.

The Pulsatility Study

A targeted pulsatility study at 60 and 90 µg/kg doses found that one week after injection, mean GH secretion was increased by approximately 50%, mean IGF-1 was significantly elevated, and the greatest increases were observed in trough GH levels — which rose 7.8-fold. GH pulse amplitude and pulse frequency were both preserved, confirming that continuous GHRH-receptor stimulation via albumin-bound CJC-1295 does not suppress the somatostatin-modulated pulsatile rhythm of GH secretion.

The In Vivo Albumin Bioconjugation Study

The discovery study that identified CJC-1295 as the optimal lead compound from three maleimido-GRF derivatives confirmed that the peptide showed a 4-fold increase in GH area under the curve over a 2-hour period compared to hGRF(1-29) in rats, with Western blot analysis detecting CJC-1295-albumin conjugate in plasma from 15 minutes post-injection through beyond 24 hours — establishing the in vivo bioconjugation mechanism as both rapid and durable.

GHRH-Knockout Growth Normalisation

The GHRH-knockout mouse study established that continuous GHRH-receptor stimulation via CJC-1295 DAC is capable of not only restoring GH secretion but normalising growth phenotype, body composition, and pituitary histology in a model of complete GHRH deficiency — a research achievement that was not possible with conventional short-acting GHRH analogues even at twice-daily dosing frequency.

Key cited studies:

• Teichman SL et al. (2006) — Prolonged Stimulation of GH and IGF-1 Secretion by CJC-1295, a Long-Acting Analog of GHRH, in Healthy Adults — J Clin Endocrinol Metab 91(3):799–805. DOI: 10.1210/jc.2005-1536. PubMed ID: 16352683
• Ionescu M & Frohman LA (2006) — Pulsatile Secretion of GH Persists During Continuous Stimulation by CJC-1295, a Long-Acting GHRH Analog — J Clin Endocrinol Metab 91(12):4792–4797. PubMed ID: 17018654
• Jetté L et al. (2005) — hGRF(1-29)-Albumin Bioconjugates Activate the GRF Receptor; Identification of CJC-1295 as a Long-Lasting GRF Analog — Endocrinology 146(7):3052–3058. PubMed ID: 15817669
• Alba M et al. (2006) — Once-Daily Administration of CJC-1295 Normalises Growth in the GHRH-Knockout Mouse — Am J Physiol Endocrinol Metab 291(6):E1290–E1294. PubMed ID: 16822960
• Sackmann-Sala L et al. (2009) — Activation of the GH/IGF-1 Axis by CJC-1295 Results in Serum Protein Profile Changes in Normal Adult Subjects — Growth Horm IGF Res 19(6):471–477. DOI: 10.1016/j.ghir.2009.03.001

CJC-1295 With DAC vs Other GHRH-Class Research Peptides

Feature	CJC-1295 With DAC	CJC-1295 Without DAC	Sermorelin	Tesamorelin
Half-Life Extension Mechanism	Covalent albumin bioconjugation (DAC)	None (4 amino acid substitutions only)	None (C-terminal amidation only)	trans-3-hexenoyl N-terminal cap
Half-Life	6–8 days	~30 minutes	~11–12 minutes	~26–38 minutes
GH Elevation Duration	6+ days per dose	Hours	Minutes to hours	Hours
IGF-1 Elevation Duration	9–28 days (cumulative)	Hours	Hours	Hours
GH Release Pattern	Sustained with preserved pulsatility	Physiological pulsatile	Physiological pulsatile	Physiological pulsatile
Somatotroph Proliferation Data	Confirmed (GHRHKO mouse)	Confirmed (GHRHKO mouse)	Yes (pituitary reserve data)	Limited
Clinical Trial Data	Phase 1/2 — 2 RCTs in healthy adults	Pre-clinical only (as standalone)	FDA-approved (diagnostic, discontinued)	Phase 3 (HIV lipodystrophy)
Receptor Desensitisation Risk	Higher (continuous occupancy)	Low	Low	Low
Research Utility	Sustained GH axis elevation, trough modelling	Pulsatile GH axis research	Reference pulsatile GHRH model	VAT/lipid research focus

CJC-1295 DAC’s unique albumin-binding pharmacokinetics make it the only GHRH-class compound capable of providing sustained, multi-day GHRH-receptor engagement from a single administration — enabling a category of research into prolonged GH axis stimulation, somatotroph reserve expansion, serum proteomics, and sustained vs pulsatile GH biology that no other GHRH analogue can replicate.

Quality & Purity Assurance

Every batch of CJC-1295 With DAC from Peptides Lab UK is:

• >99% pure — HPLC and mass spectrometry verified
• Supplied with a full Certificate of Analysis (COA) on request
• Lyophilised powder for maximum stability and long shelf life
• Manufactured under strict, controlled laboratory conditions
• Consistent batch-to-batch quality for reproducible research results

Buy CJC-1295 With DAC UK — Product Specifications

Property	Detail
Full Name	CJC-1295 DAC / DAC:GRF / DAC-GHRH (1-29)
Developed By	ConjuChem Biotechnologies
Sequence	H-Tyr-D-Ala²-Asp-Ala-Ile-Phe-Thr-Gln⁸-Ser-Tyr-Arg-Lys-Val-Leu-Ala¹⁵-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu²⁷-Ser-Arg-(Nε-maleimidopropionyl-)Lys³⁰-NH₂
Amino Acids	30 (29 aa GHRH backbone + DAC lysine derivative at C-terminus)
Half-Life Extension	Covalent in vivo bioconjugation to serum albumin (Cys34)
Effective Half-Life	6–8 days (humans)
Molecular Weight	~3,647 Da
Purity	>99% (HPLC verified)
Form	Lyophilised powder
Storage	Store dry at -20°C; protect from light
Solubility	Bacteriostatic water, sterile water, or suitable laboratory solvents

CJC-1295 With DAC Research Applications

CJC-1295 DAC peptide UK is supplied strictly for the following in vitro and pre-clinical research uses:

• Sustained GHRH receptor engagement, cAMP/PKA signalling, and continuous somatotroph stimulation studies
• GH trough and mean concentration elevation under preserved pulsatile architecture research
• Somatotroph cell proliferation, pituitary reserve expansion, and GH mRNA transcription studies
• IGF-1 axis prolonged elevation and downstream anabolic signalling pathway investigations
• GH/IGF-1-responsive serum proteome remodelling and biomarker discovery research
• GHRH-knockout (GHRHKO) mouse growth normalisation and interval-dependent dosing research
• Comparative sustained vs pulsatile GH secretion pharmacology — CJC-1295 DAC vs no-DAC, Sermorelin, and Tesamorelin
• Metabolic pathway research — lipid oxidation, glucose homeostasis, and body composition modelling
• Albumin bioconjugation pharmacokinetics and DAC technology mechanism-of-action studies
• GH axis negative feedback — somatostatin interplay and IGFBP regulatory response under prolonged GHRH-R occupancy

Why Buy CJC-1295 With DAC from Peptides Lab UK?

Peptides Lab UK is a trusted UK peptides supplier, providing research-grade compounds verified by independent HPLC testing. When you buy CJC-1295 DAC in the UK from us, you receive:

• >99% purity, HPLC and MS verified, third-party tested
• Full COA documentation per batch
• Fast same-day UK dispatch with tracked delivery
• Competitive pricing with bulk research discounts available
• Trusted by researchers across the UK and Europe

Research Disclaimer All products supplied by Peptides Lab UK are intended strictly for in vitro laboratory research and scientific study use only. They are not intended for human consumption, veterinary use, or any medical or therapeutic application. CJC-1295 With DAC is not a licensed medicine or drug and has not been approved by the MHRA, FDA, or any regulatory authority for use in humans or animals. CJC-1295 DAC entered Phase 2 clinical trials but development was discontinued by ConjuChem Biotechnologies; it has no regulatory approval. CJC-1295 DAC, as a GHRH analogue, is classified as a prohibited substance under WADA regulations and is not approved for use in sport or competition. All research citations on this page relate to pre-clinical studies and peer-reviewed pharmacological research and do not constitute a claim of safety or therapeutic efficacy. Peptides Lab UK accepts no liability for any misuse of research compounds. By purchasing, you confirm that you are a qualified researcher and that the product will be used solely within a controlled laboratory environment in compliance with all applicable UK laws, regulations, and institutional guidelines.